Clear Investment Research LLC Grows Stock Holdings in Eli Lilly and Company $LLY

Clear Investment Research LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 0.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,695 shares of the company’s stock after purchasing an additional 22 shares during the quarter. Eli Lilly and Company comprises approximately 2.7% of Clear Investment Research LLC’s portfolio, making the stock its 10th largest holding. Clear Investment Research LLC’s holdings in Eli Lilly and Company were worth $2,101,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in LLY. Lazard Freres Gestion S.A.S. boosted its position in Eli Lilly and Company by 114.3% during the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after buying an additional 41,222 shares during the period. Precedent Wealth Partners LLC boosted its position in Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after buying an additional 39 shares during the period. Capital Advisors Inc. OK boosted its position in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares during the period. Family CFO Inc purchased a new stake in Eli Lilly and Company during the second quarter valued at about $54,000. Finally, Duquesne Family Office LLC boosted its position in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 4,514 shares of company stock valued at $2,894,841 over the last quarter. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

LLY stock opened at $842.28 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The company has a market cap of $797.18 billion, a P/E ratio of 55.05, a PEG ratio of 1.21 and a beta of 0.47. The firm has a 50-day moving average of $777.69 and a 200 day moving average of $770.84. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Analyst Upgrades and Downgrades

LLY has been the subject of several analyst reports. Leerink Partners restated a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. JPMorgan Chase & Co. decreased their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Guggenheim restated a “buy” rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Finally, The Goldman Sachs Group boosted their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $936.47.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.